Prognostic value of pan-immune-inflammation index in hepatocellular carcinoma compared with albumin-bilirubin and model for end-stage liver disease sodium

doi:10.4251/wjgo.v18.i7.121250

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

(21)

(18)

(0)

(1)

(310)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Jul 15, 2026; 18(7): 121250
Published online Jul 15, 2026. doi: 10.4251/wjgo.v18.i7.121250

Table 1 Baseline characteristics of the study population (n = 97), n (%)

Variable
Age, years	Median 68 (range: 27-87)
Sex
Female	20 (20.6)
Male	77 (79.4)
ECOG performance status
0	31 (32.0)
1	41 (42.3)
2	13 (13.4)
3	11 (11.3)
4	1 (1.0)
Etiology
Hepatitis B	53 (54.6)
Hepatitis C	8 (8.3)
Alcohol-related	15 (15.5)
Non-alcoholic	21 (21.6)
Cirrhosis
Absent	59 (60.8)
Present	38 (39.2)
BCLC stage
A	30 (30.9)
B	14 (14.4)
C	34 (35.1)
D	19 (19.6)
Tumor number
Single	28 (28.9)
2-3 lesions	20 (20.6)
Multiple (≥ 4)	49 (50.5)
Vascular invasion
Absent	63 (64.9)
Present	34 (35.1)
Treatment modality
Liver transplantation	4 (4.1)
Surgical resection	22 (22.7)
TACE/TARE	9 (9.3)
Sorafenib	33 (34.0)
Atezolizumab + bevacizumab	3 (3.1)
Best supportive care	18 (18.6)
Radiofrequency ablation	7 (7.2)
FOLFOX	1 (1.0)

ECOG: Eastern Cooperative Oncology Group; BCLC: Barcelona Clinic Liver Cancer staging system; TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization.

Full Size Table

Citation: Karatlı S, Yazılıtaş D, Kaya S, İmamoğlu Gİ, Çelik S, Uyar GC. Prognostic value of pan-immune-inflammation index in hepatocellular carcinoma compared with albumin-bilirubin and model for end-stage liver disease sodium. World J Gastrointest Oncol 2026; 18(7): 121250
URL: https://www.wjgnet.com/1948-5204/full/v18/i7/121250.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i7.121250

Karatlı S, Yazılıtaş D, Kaya S, İmamoğlu Gİ, Çelik S, Uyar GC. Prognostic value of pan-immune-inflammation index in hepatocellular carcinoma compared with albumin-bilirubin and model for end-stage liver disease sodium. World J Gastrointest Oncol 2026; 18(7): 121250 [DOI: 10.4251/wjgo.v18.i7.121250]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.